Doxazosin Mesylate
Product Images NDC 68258-6099

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Doxazosin Mesylate (NDC 68258-6099). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dispensing Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Doxazosin Mesylate Molecular Structure (4abe1804 Ae5f 4401 B84c 8ca6a71fbf74 01)

Chemical structure of the active ingredient Doxazosin Mesylate, showing its molecular arrangement with methoxy groups, a piperazine ring, and a benzodioxane moiety along with the methanesulfonic acid (mesylate) part.*

FDA Label Image

Table 1: Summary Of Effectiveness Data In Placebo-controlled Trials (4abe1804 Ae5f 4401 B84c 8ca6a71fbf74 02)

A data table titled 'SUMMARY OF EFFECTIVENESS DATA IN PLACEBO-CONTROLLED TRIALS' comparing symptom scores and maximum flow rates (mL/sec) across three studies for placebo and doxazosin mesylate treatments at 4 mg and 8 mg doses. The table includes mean baseline values and mean changes, with statistical significance indicated. Additionally, a bar graph visually represents symptom score and maximum flow rate changes in Study 2 for placebo, 4 mg, and 8 mg doses, accompanied by explanatory footnotes about questionnaire types, study populations, and significance markers.*

FDA Label Image

Graph: Mean Change In Total Symptom Score From Baseline (4abe1804 Ae5f 4401 B84c 8ca6a71fbf74 03)

Line graph titled 'Figure 1-Study 1' showing mean change in total symptom score from baseline over 14 weeks. It compares two groups: placebo (N=47) and doxazosin mesylate (N=50). The x-axis represents duration of treatment in weeks, and the y-axis shows mean change, ranging from 0 to -6. The doxazosin mesylate group shows a greater decrease in symptom score over time compared to placebo, with error bars indicating variability.*

FDA Label Image

Graph: Mean Increase In Maximum Urinary Flow Rate (ml/sec) From Baseline (4abe1804 Ae5f 4401 B84c 8ca6a71fbf74 04)

A line graph showing mean increase in maximum urinary flow rate (mL/sec) from baseline over 14 weeks of treatment. It compares doxazosin mesylate (N=50) with placebo (N=47), indicating higher increases in flow rate with doxazosin mesylate, with statistical significance at multiple points during the treatment period.*

FDA Label Image

Ndc 68258-6099-xx (Ndc 68258 6099 Xx Patheon)

Label for Doxazosin Mesylate 1 mg tablets by Dispensing Solutions, Inc. The label states product NDC 68258-6099 with package size indicated as 'XX tablets'. It includes dosing instructions to take once daily orally, either in the morning or at bedtime, with guidance to consult a physician if dizziness or light-headedness occurs. The label also indicates the product is prescription only (Rx only) and notes storage instructions and warnings to keep out of children's reach.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.